- Home
- VMD vs SCTX Comparison
VMD vs SCTX Comparison
Compare VMD & SCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VMD | SCTX |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 465.4M | 536.5M |
| IPO Year | 2018 | 2026 |
Fundamental Metrics
Financial Performance| Metric | VMD | SCTX |
|---|---|---|
| Price | $8.91 | $21.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 247.8K | 247.2K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.14 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $270,280,000.00 | N/A |
| Revenue This Year | $17.88 | N/A |
| Revenue Next Year | $14.98 | N/A |
| P/E Ratio | $67.85 | ★ N/A |
| Revenue Growth | ★ 20.52 | N/A |
| 52 Week Low | $6.05 | $17.31 |
| 52 Week High | $12.61 | $39.60 |
Technical Indicators
Market Signals| Indicator | VMD | SCTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.38 | 36.49 |
| Support Level | $8.52 | $19.09 |
| Resistance Level | $9.00 | $26.50 |
| Average True Range (ATR) | 0.20 | 3.74 |
| MACD | 0.06 | -1.25 |
| Stochastic Oscillator | 61.44 | 6.39 |
Price Performance
Historical ComparisonAbout VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings focus on effective in-home treatment, with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The company generates the majority of its revenue from medical equipment rental, sales, and supply.
About SCTX Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.